sub:assertion {
  <http://purl.obolibrary.org/obo/DOID_2050> bl:category bl:Disease .
  sub:association rdf:object <http://purl.obolibrary.org/obo/DOID_2050> ;
    rdf:predicate bl:treats ;
    rdf:subject <https://identifiers.org/drugbank:DB01416> ;
    a rdf:Statement ;
    rdfs:label "cefpodoxime proxetil is indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below recommended dosages durations of therapy and applicable patient populations vary among these infections please see dosage and administration acute otitis media streptococcus pneumoniae streptococcus pyogenes haemophilus influenzae moraxella branhamella catarrhalis pharyngitis and or tonsillitis streptococcus pyogenes note community acquired pneumonia s pneumoniae h influenzae acute bacterial exacerbation of chronic bronchitis s pneumoniae h influenzae m catarrhalis h influenzae acute uncomplicated urethral and cervical gonorrhea neisseria gonorrhoeae acute uncomplicated ano rectal infections in women neisseria gonorrhoeae note n gonorrhoeae n gonorrhoeae uncomplicated skin and skin structure infections staphylococcus aureus streptococcus pyogenes note dosage and administration acute maxillary sinusitis haemophilus influenzae streptococcus pneumoniae moraxella catarrhalis uncomplicated urinary tract infections cystitis escherichia coli klebsiella pneumoniae proteus mirabilis staphylococcus saprophyticus note clinical studies appropriate specimens for bacteriological examination should be obtained in order to isolate and identify causative organisms and to determine their susceptibility to cefpodoxime therapy may be instituted while awaiting the results of these studies once these results become available antimicrobial therapy should be adjusted accordingly to reduce the development of drug resistant bacteria and maintain the effectiveness of cefpodoxime proxetil for oral suspension usp and other antibacterial drugs cefpodoxime proxetil for oral suspension usp should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria when culture and susceptibility information are available they should be considered in selecting or modifying antibacterial therapy in the absence of such data local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy" ;
    bl:association_type bl:ChemicalToDiseaseOrPhenotypicFeatureAssociation ;
    bl:provided_by <https://w3id.org/um/NeuroDKG> ;
    bl:relation schema:TreatmentIndication .
  <https://identifiers.org/drugbank:DB01416> bl:category bl:Drug .
}